Loading
Life sciences · Journal article
Expert Opinion on Drug Delivery · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Effective diagnostic and therapeutic strategies for cancer remain limited by poor specificity, systemic toxicity, and biological barriers because of the heterogeneity of cancers. To overcome these obstacles, nanomedicines have been increasingly explored. Among the different nanoscale systems, metal-organic frameworks (MOFs) are promising platforms because of their ultra-high porosity, modular chemical composition, and tunable architecture by design. Moreover, MOFs can facilitate both drug release for cancer treatment and imaging through the combination of imaging agents and therapeutics. AREAS COVERED: A comprehensive review of the properties, benefits, and clinical trials of MOFs for breast cancer diagnosis and treatment is lacking. We review the current status and advances of MOFs used for breast cancer diagnosis and drug delivery using publications primarily from PubMed through July 2026. We also discuss new strategies that take advantage of the unique physicochemical properties of MOFs for breast cancer theranostics. EXPERT OPINION: Multifunctional nanoplatforms based on MOFs have promise in revolutionizing precision oncology in breast cancer. With the ongoing developments in synthetic chemistry, bioengineering, and computer modeling, MOFs may represent resources for personalized therapeutics combining diagnosis, treatment, and monitoring of response. Subsequent interdisciplinary investigations will be important in translating the preclinical findings into clinical applications.